Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
- PMID: 10353864
- DOI: 10.1086/314837
Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
Abstract
Lymphoproliferative responses (LPRs) to recall antigens (Ags) and human immunodeficiency virus type 1 (HIV-1) Gag and frequencies of circulating HIV-1-specific cytotoxic T lymphocyte precursors (CTLps) were measured in 12 patients undergoing highly active antiretroviral therapy (HAART) after long-standing HIV-1 infection. LPRs to at least 1 recall Ag became detectable or increased in all patients during HAART. No significant LPRs to Gag-p24 were observed, whereas 4 of 8 patients tested presented with Gag-p17-specific LPRs. HIV-1-specific CTLp frequencies became measurable or increased early during therapy in 6 of 10 patients tested and were maintained or decreased thereafter. Increasing HIV-1-specific CTLp frequencies were seen only in association with partial HAART failure in 1 patient. In conclusion, restoration of CD4+ T lymphocyte responsiveness to recall Ags is achieved during HAART. The data provide evidence for limited HIV-1-specific CD4+ memory T cells during advanced HIV-1 infection and suggest that both CD4+ and CD8+ HIV-1-specific T cells are poorly stimulated when viral load is suppressed.
Similar articles
-
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).J Immunol. 1999 Feb 1;162(3):1780-8. J Immunol. 1999. PMID: 9973442
-
The CD160+ CD8high cytotoxic T cell subset correlates with response to HAART in HIV-1+ patients.Cell Immunol. 2005 Oct;237(2):96-105. doi: 10.1016/j.cellimm.2005.01.012. Epub 2005 Dec 9. Cell Immunol. 2005. PMID: 16337931
-
Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy.J Infect Dis. 2000 Apr;181(4):1264-72. doi: 10.1086/315381. Epub 2000 Apr 5. J Infect Dis. 2000. PMID: 10751137
-
Lymphocyte-proliferative responses to HIV antigens as a potential measure of immunological reconstitution in HIV disease.AIDS Res Hum Retroviruses. 1998 Jun;14 Suppl 2:S161-6. AIDS Res Hum Retroviruses. 1998. PMID: 9672234 Review.
-
Cellular immune responses to HIV-1.AIDS. 1998;12 Suppl A:S113-20. AIDS. 1998. PMID: 9632992 Review. No abstract available.
Cited by
-
Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjects.Clin Diagn Lab Immunol. 2001 Jul;8(4):671-7. doi: 10.1128/CDLI.8.4.671-677.2001. Clin Diagn Lab Immunol. 2001. PMID: 11427409 Free PMC article. Review. No abstract available.
-
CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART.Clin Exp Immunol. 2001 Nov;126(2):295-303. doi: 10.1046/j.1365-2249.2001.01680.x. Clin Exp Immunol. 2001. PMID: 11703374 Free PMC article. Clinical Trial.
-
Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses.J Virol. 2002 Mar;76(6):2817-26. doi: 10.1128/jvi.76.6.2817-2826.2002. J Virol. 2002. PMID: 11861849 Free PMC article.
-
Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study.Vaccine. 2011 Feb 11;29(8):1617-23. doi: 10.1016/j.vaccine.2010.12.066. Epub 2011 Jan 4. Vaccine. 2011. PMID: 21211581 Free PMC article. Clinical Trial.
-
Engineering T Cells to Functionally Cure HIV-1 Infection.Mol Ther. 2015 Jul;23(7):1149-1159. doi: 10.1038/mt.2015.70. Epub 2015 Apr 21. Mol Ther. 2015. PMID: 25896251 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials